CytRx Corporation announced plans to initiate a Phase 2 trial in the second half of 2010 to evaluate the effectiveness and safety of its drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer. This planned international proof-of-concept trial is expected to enroll up to 50 patients with metastatic hormone-refractory prostate cancer who have failed first-line therapy with either the chemotherapy agent docetaxel or mitoxantrone. The trial endpoints will be reduction in prostate-specific antibodies and increase in progression-free survival compared to baseline and historical data.
Bafetinib is a potent, orally available, rationally designed, dual Bcr-Abl and Lyn kinase inhibitor.
For more information call (310) 826-5648 or visit www.cytrx.com.